Deliver chemotherapy directly in the tumor
TG6002 is an oncolytic virus that allows the production of a chemotherapy agent directly in the tumor.
TG6002, when administered intravenously or via the hepatic artery, replicates selectively in tumor cells, resulting in the local production of 5-FU.
This specific mechanism of action allows for the targeted destruction of the tumor while stimulating the patient’s immune response locally. With its selective mechanism of action, TG6002 could offer a real alternative to chemotherapeutic agents, which due to their systemic administration, have many associated side effects.
Two Phase I/II clinical trials are enrolling patients in Europe.